Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation-Reference-Cited by-同舟云学术

Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation

Published:2019-08 Issue:8 Volume:25 Page:1689-1694
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Abedin Sameem,McKenna Edward,Chhabra Saurabh,Pasquini Marcelo,Shah Nirav N.,Jerkins James,Baim Arielle,Runaas Lyndsey,Longo Walter,Drobyski William,Hari Parameswaran N.,Hamadani Mehdi

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference18 articles.

1. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey;Zeiser;Leukemia,2015

2. Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients;Khandelwal;Biol Blood Marrow Transplant,2017

3. Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease;Khoury;Bone Marrow Transplant,2018

4. B cell IFN-γ receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6;Jackson;J Exp Med,2016

5. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease;Chen;Blood,2009

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of early post-hematopoietic stem cell transplant tacrolimus concentration on transplant outcomes in pediatric recipients: One facility’s ten-year experience of immunosuppression with tacrolimus;International Immunopharmacology;2024-09

2. New investigational drugs for steroid-refractory acute graft-versus-host disease: a review of the literature;Expert Opinion on Investigational Drugs;2024-07-09

3. Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis;Annals of Hematology;2024-06-25

4. Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients;Bone Marrow Transplantation;2024-04-05

5. Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update;Critical Care;2024-03-05